EA199800970A1 - Терапевтическое лечение глазных заболеваний, связанных с фактором роста сосудистого эндотелия - Google Patents

Терапевтическое лечение глазных заболеваний, связанных с фактором роста сосудистого эндотелия

Info

Publication number
EA199800970A1
EA199800970A1 EA199800970A EA199800970A EA199800970A1 EA 199800970 A1 EA199800970 A1 EA 199800970A1 EA 199800970 A EA199800970 A EA 199800970A EA 199800970 A EA199800970 A EA 199800970A EA 199800970 A1 EA199800970 A1 EA 199800970A1
Authority
EA
Eurasian Patent Office
Prior art keywords
growth factor
therapeutic treatment
diseases associated
eye diseases
vascular endothelium
Prior art date
Application number
EA199800970A
Other languages
English (en)
Other versions
EA001752B1 (ru
Inventor
Ллойд П. Аиелло
Майкл Р. Джироусек
Джордж Л. Кинг
Луис Виньяти
Дуглас Кирк Вэйс
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199800970A1 publication Critical patent/EA199800970A1/ru
Publication of EA001752B1 publication Critical patent/EA001752B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Описывается способ ингибирования роста эндотелиальных клеток, стимулированного ФРСЭ, такого как связанного с дегенерацией желтого пятна, и стимулированной ФРСЭ капиллярной проницаемости, такой как связанной с отеком желтого пятна, в частности с использованием селективного ПКС ингибитора изофермента, хлористо-водородной соли (S)-3,4-[N,N'-1,1'-((2"-этокси)-3"'(О)-4"'-(N,N-диметиламино)-бутан)-бис-(3,3'-индолил)]-1(Н)-пиррол-2,5-диона.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800970A 1996-05-01 1997-05-01 Терапевтическое лечение глазных заболеваний, связанных с фактором роста сосудистого эндотелия EA001752B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1665896P 1996-05-01 1996-05-01
US08/841,739 US6114320A (en) 1996-05-01 1997-04-30 Therapeutic treatment for VEGF related ocular diseases
PCT/US1997/007800 WO1997040831A1 (en) 1996-05-01 1997-05-01 Therapeutic treatment for vegf related occular diseases

Publications (2)

Publication Number Publication Date
EA199800970A1 true EA199800970A1 (ru) 1999-06-24
EA001752B1 EA001752B1 (ru) 2001-08-27

Family

ID=26688915

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800970A EA001752B1 (ru) 1996-05-01 1997-05-01 Терапевтическое лечение глазных заболеваний, связанных с фактором роста сосудистого эндотелия

Country Status (22)

Country Link
US (1) US6114320A (ru)
EP (1) EP0918519B1 (ru)
JP (1) JP4122060B2 (ru)
KR (1) KR100364487B1 (ru)
CN (1) CN1158073C (ru)
AT (1) ATE270548T1 (ru)
AU (1) AU724923B2 (ru)
BR (1) BR9710705A (ru)
CA (1) CA2253613C (ru)
CZ (1) CZ296711B6 (ru)
DE (1) DE69729798T2 (ru)
EA (1) EA001752B1 (ru)
ES (1) ES2224249T3 (ru)
HK (1) HK1020017A1 (ru)
HU (1) HU226378B1 (ru)
IL (1) IL126836A (ru)
NO (1) NO322209B1 (ru)
NZ (2) NZ332833A (ru)
PL (1) PL189020B1 (ru)
PT (1) PT918519E (ru)
UA (1) UA54427C2 (ru)
WO (1) WO1997040831A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
DK1105136T3 (da) * 1998-08-13 2007-10-15 Novartis Ag Fremgangsmåde til behandling af okulære neovaskulære sygdomme
NZ511559A (en) * 1998-11-23 2004-01-30 Novartis Ag Use of staurosporine derivatives for treating ocular neovascular diseases
US6214819B1 (en) 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
IL143596A0 (en) * 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
WO2001057008A1 (en) 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
WO2004009056A1 (en) * 2002-07-23 2004-01-29 Novartis Ag Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
US20040258769A1 (en) * 2003-06-20 2004-12-23 Barker Ronnie C. Use of ocular vitamins in conjunction with other treatment methods for AMD
EP1727529B1 (en) * 2004-03-17 2016-03-02 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
DK1740591T3 (da) 2004-04-02 2009-10-26 Osi Pharm Inc Heterobicykliske proteinkinaseinhibitorer substitueret med en 6,6-biocyclisk ring
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US7455447B2 (en) * 2006-05-19 2008-11-25 Mediatek Inc. Method and apparatus for a portable device
JP2010501586A (ja) * 2006-08-23 2010-01-21 ノバルティス アクチエンゲゼルシャフト 眼疾患におけるｐｋｃ阻害剤、特にインドリルマレイミド誘導体の使用
EP2089016A4 (en) * 2006-10-03 2014-10-08 Univ Pennsylvania METHOD FOR TREATING MACULAR AGENCY
US10360673B2 (en) 2015-03-26 2019-07-23 Eyekor, Llc Image analysis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
DE69428025T2 (de) * 1993-12-07 2002-05-29 Lilly Co Eli Proteinkinase C-Inhibitoren
DK0657411T3 (da) * 1993-12-07 1999-11-15 Lilly Co Eli Forbedret syntese af bisindolylmaleimider
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
DE69729798T2 (de) 2005-08-25
CZ349998A3 (cs) 1999-11-17
NZ538109A (en) 2006-10-27
ATE270548T1 (de) 2004-07-15
NO322209B1 (no) 2006-08-28
WO1997040831A1 (en) 1997-11-06
EP0918519A4 (en) 1999-08-11
PL330463A1 (en) 1999-05-24
DE69729798D1 (de) 2004-08-12
JP2000514402A (ja) 2000-10-31
AU2936197A (en) 1997-11-19
CZ296711B6 (cs) 2006-05-17
UA54427C2 (ru) 2003-03-17
HUP9902805A3 (en) 2000-04-28
IL126836A0 (en) 1999-09-22
US6114320A (en) 2000-09-05
HU226378B1 (en) 2008-10-28
EP0918519A1 (en) 1999-06-02
ES2224249T3 (es) 2005-03-01
NO985067D0 (no) 1998-10-30
HUP9902805A2 (hu) 2000-02-28
EP0918519B1 (en) 2004-07-07
KR20000065172A (ko) 2000-11-06
KR100364487B1 (ko) 2003-01-25
EA001752B1 (ru) 2001-08-27
PT918519E (pt) 2004-10-29
CN1158073C (zh) 2004-07-21
BR9710705A (pt) 1999-08-17
NZ332833A (en) 2000-07-28
AU724923B2 (en) 2000-10-05
PL189020B1 (pl) 2005-06-30
NO985067L (no) 1998-12-22
CN1222850A (zh) 1999-07-14
IL126836A (en) 2004-05-12
CA2253613C (en) 2007-11-27
JP4122060B2 (ja) 2008-07-23
CA2253613A1 (en) 1997-11-06
HK1020017A1 (en) 2000-03-10

Similar Documents

Publication Publication Date Title
EA199800970A1 (ru) Терапевтическое лечение глазных заболеваний, связанных с фактором роста сосудистого эндотелия
EA199800969A1 (ru) Способ лечения заболеваний, связанных с фактором роста сосудистого эндотелия
EA199800971A1 (ru) Способ лечения новообразований, вкючающий применение ингибиторов протеиназы с
ATE315933T1 (de) Therapeutische behandlung von kardiovaskularen krankheiten
ES2127558T3 (es) Agentes conservantes.
EA199900987A1 (ru) Терапевтическое лечение заболеваний кожи
DE69709273T2 (de) Verwendung von PKC-Hemmern zur Herstellung eines Arzneimittels zur Behandlung von Sexualfunktionsstörungen
EA199900245A1 (ru) Использование ингибиторов протеинкиназы с для получения лекарственного препарата для лечения спида
DE69935881D1 (de) Bis-Indolylmaleimide zur therapeutischen Behandlung von Nieren-Funktionsstörungen
EA199900243A1 (ru) Применение ингибиторов протеинкиназы с для производства лекарственного препарата для лечения инфекции, вызванной человеческим т-клеточным лимфотропным вирусом типа 1
NO990947L (no) Anvendelse av inhibitorer for PKC til fremstilling av et medikament for behandling av sentralnervesystemsykdommer forbundet med HIV-infeksjon
UA31903A (uk) Спосіб лікування хронічного неспецифічного простатиту

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU